Q1 2027 saw 16% revenue growth and 19% higher operating profit, driven by LENVIMA, DAYVIGO, and Leqembi. Key products expanded market share, new indications and reimbursement advances support outlook, and pipeline progress continues in AD and orexin platforms.Based on Eisai Co., Ltd. [4523] Q1 2027…
Revenue and profit rose sharply year-over-year, led by strong sales of Lenvima, Leqembi, and Dayvigo, and supported by favorable currency effects. FY2026 guidance remains unchanged, with robust growth expected across all major segments.Original document: Eisai Co., Ltd. [4523] Interim report — Aug…
TOKYO, July 27, 2026 - (JCN Newswire) - Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Hiroo Igarashi, "Pfizer") and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the companies will commence the co-promotion of the oral calcito…
TOKYO and CAMBRIDGE, Mass., July 15, 2026 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application(sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (U.S. brand…
TOKYO, July 15, 2026 - (JCN Newswire) - Eisai Co., Ltd. today announced the latest findings on etalanetug (development code: E2814) showed that this investigational anti-MTBR antibody reduced levels of plasma eMTBRtau243, a key biomarker of Alzheimer's disease (AD) tau tangle pathology. The investi…
TOKYO and CAMBRIDGE, Mass., July 13, 2026 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB)announced today that new data presented at the Alzheimer's Association International Conference(R)(AAIC(R)) 2026 in London support that the LEQEMBI(R) (lecanemab) subcutaneous autoinjector (SC…
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosingfor initiation and maintenance (approved in the U.S.)U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co…
